BMC321 / Evogene - LARVOL DELTA

Biomica Reports Positive Results from Pre-Clinical Studies in its Inflammatory Bowel Disease (IBD) Program (PRNewswire) - "Biomica...a subsidiary of Evogene Ltd...reported today positive results from pre-clinical studies in its IBD program. In these studies, Biomica tested its optimized drug candidate BMC333, which consists of four live bacterial strains derived from Biomica's drug candidates BMC321 and BMC322, which had been previously tested as well. Treatment with these drug candidates demonstrated efficacy in several studies in reducing inflammation for the treatment of IBD...Looking forward, Biomica expects to begin the scale-up development processes of BMC333 in 2022, in preparation for the production of an initial clinical batch."

Preclinical • Immunology • Inflammatory Bowel Disease

Evogene: Q3 Update And Upcoming Catalysts (SeekingAlpha) - "Biomica Ltd. is advancing its rationally designed multi-strand live microbiome biotherapeutics programs in 3 main disease targets including:...IBD (inflammatory bowel disease); and...H1 2021 (my estimate) - Preclinical results released from BMC321 / BMC322 in treatment of IBD in studies currently being conducted at the University of North Carolina at the lab of Professor Balfour Sartor."

Preclinical • Inflammatory Bowel Disease